CR Sanjiu Logs 18% Boost in 2024 Profit

MT Newswires Live

2025/03/13

China Resources Sanjiu Medical & Pharmaceutical (SHE:000999) recorded an 18% rise in attributable profit for 2024 to 3.37 billion yuan from 2.85 billion yuan a year prior, a Wednesday filing by parent China Resources Pharmaceutical Group (HKG:3320) with the Hong Kong bourse said.

Earnings per share were 2.63 yuan in the year, up from 2.23 yuan in the last fiscal year.

The drug company's revenue rose by 12% to 27.6 billion yuan in the period from 24.7 billion yuan a year prior.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2519005605"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2519005605\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2519005605?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-13 15:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2519005605","market":"sg","top_or_hot":-1,"title":"CR Sanjiu Logs 18% Boost in 2024 Profit","media":"MT Newswires Live","content":"<html><body><p> China Resources Sanjiu Medical &amp; Pharmaceutical (SHE:000999) recorded an 18% rise in attributable profit for 2024 to 3.37 billion yuan from 2.85 billion yuan a year prior, a Wednesday filing by parent China Resources Pharmaceutical Group (HKG:3320) with the Hong Kong bourse said.</p><p>Earnings per share were 2.63 yuan in the year, up from 2.23 yuan in the last fiscal year.</p><p>The drug company's revenue rose by 12% to 27.6 billion yuan in the period from 24.7 billion yuan a year prior.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CR Sanjiu Logs 18% Boost in 2024 Profit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCR Sanjiu Logs 18% Boost in 2024 Profit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-13 15:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> China Resources Sanjiu Medical &amp; Pharmaceutical (SHE:000999) recorded an 18% rise in attributable profit for 2024 to 3.37 billion yuan from 2.85 billion yuan a year prior, a Wednesday filing by parent China Resources Pharmaceutical Group (HKG:3320) with the Hong Kong bourse said.</p><p>Earnings per share were 2.63 yuan in the year, up from 2.23 yuan in the last fiscal year.</p><p>The drug company's revenue rose by 12% to 27.6 billion yuan in the period from 24.7 billion yuan a year prior.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2519005605","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2519005605","pubTimestamp":1741850114,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China Resources Sanjiu Medical & Pharmaceutical  recorded an 18% rise in attributable profit for 2024 to 3.37 billion yuan from 2.85 billion yuan a year prior, a Wednesday filing by parent China Resources Pharmaceutical Group  with the Hong Kong bourse said.Earnings per share were 2.63 yuan in the year, up from 2.23 yuan in the last fiscal year.The drug company's revenue rose by 12% to 27.6 billion yuan in the period from 24.7 billion yuan a year prior.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","CR":"crane","BK1570":"华润系","BK0188":"融资融券","BK0012":"证金概念","BK0175":"白马股","BK0196":"行业龙头","03320":"华润医药","000999":"华润三九","BK0239":"医药制造","BK4161":"工业机械","BK0060":"抗癌","BK0010":"央企","BK0028":"国家队","BK0185":"二线龙头","BK0183":"MSCI概念"},"translate_title":"华润三九2024年利润增长18%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":0.9,"CR":1,"000999":0.9},"content_text":"China Resources Sanjiu Medical & Pharmaceutical (SHE:000999) recorded an 18% rise in attributable profit for 2024 to 3.37 billion yuan from 2.85 billion yuan a year prior, a Wednesday filing by parent China Resources Pharmaceutical Group (HKG:3320) with the Hong Kong bourse said.Earnings per share were 2.63 yuan in the year, up from 2.23 yuan in the last fiscal year.The drug company's revenue rose by 12% to 27.6 billion yuan in the period from 24.7 billion yuan a year prior.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}